Cytomegalovirus
RNAi program initiated to develop therapies for diseases associated with CMV
Published in AIDS Weekly, February 9th, 2004
Further expanding its collaboration with a developer of RNA interference (RNAi) technology, CytRx Corporation (CYTR) announced that it has signed a new agreement with the University of Massachusetts Medical School (UMMS) under which CytRx will fund research at UMMS for the further development of proprietary gene silencing technology for use in the treatment of diseases caused by cytomegalovirus (CMV), with an initial focus on CMV retinitis.
This program provides CytRx with worldwide commercial rights under an exclusive license with UMMS to any potential products that are developed based on this cutting-edge technology. It has been estimated that the healthcare burden of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2004-02-09)
More Articles from AIDS Weekly
- Drug Development
Liminoids strongly inhibit HIV protease activity - AIDS Therapy
IND application filed for protease inhibitor GS 9005 - AIDS Treatment
AIDS activists fight for more affordable drugs - AIDS and HIV
Gene product restricts HIV-1 replication in resting CD4+ lymphocytes - Education
Agreement to admit HIV-positive children into Nairobi's public schools approved - Gene Therapy
HIV vector T-cell transduction efficiency is not pseudotype-dependent - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
